Genexine, Inc. (095700.KQ)

KRW 5590.0

(-3.79%)

Long Term Debt Summary of Genexine, Inc.

Genexine, Inc.'s latest annual long term debt in 2023 was 22.68 Billion KRW , up 22.71% from previous year.
Genexine, Inc.'s latest quarterly long term debt in 2024 Q1 was 22.97 Billion KRW , up 1.28% from previous quarter.
Genexine, Inc. reported annual long term debt of 18.48 Billion KRW in 2022, down -54.53% from previous year.
Genexine, Inc. reported annual long term debt of 40.64 Billion KRW in 2021, up 157.68% from previous year.
Genexine, Inc. reported quarterly long term debt of 24.21 Billion KRW for 2024 Q2, up 5.41% from previous quarter.
Genexine, Inc. reported quarterly long term debt of 22.08 Billion KRW for 2023 Q3, up 33.62% from previous quarter.

Annual Long Term Debt Chart of Genexine, Inc. (2023 - 2012)

Historical Annual Long Term Debt of Genexine, Inc. (2023 - 2012)

Year	Long Term Debt	Long Term Debt Growth
2023	22.68 Billion KRW	22.71%
2022	18.48 Billion KRW	-54.53%
2021	40.64 Billion KRW	157.68%
2020	15.77 Billion KRW	-45.48%
2019	28.93 Billion KRW	-16.4%
2018	34.61 Billion KRW	202.05%
2017	11.45 Billion KRW	0.0%
2016	- KRW	0.0%
2015	- KRW	0.0%
2012	9.31 Billion KRW	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	22.97 Billion KRW	1.28%
2024 Q2	24.21 Billion KRW	5.41%
2023 Q3	22.08 Billion KRW	33.62%
2023 Q2	16.52 Billion KRW	-5.58%
2023 Q1	17.5 Billion KRW	-5.29%
2023 FY	22.68 Billion KRW	22.71%
2023 Q4	22.68 Billion KRW	2.7%
2022 Q2	50.75 Billion KRW	23.66%
2022 Q1	41.04 Billion KRW	0.97%
2022 FY	18.48 Billion KRW	-54.53%
2022 Q4	18.48 Billion KRW	-63.47%
2022 Q3	50.59 Billion KRW	-0.31%
2021 Q3	34.65 Billion KRW	43.33%
2021 Q4	40.64 Billion KRW	17.28%
2021 FY	40.64 Billion KRW	157.68%
2021 Q1	20.61 Billion KRW	29.11%
2021 Q2	24.18 Billion KRW	17.33%
2020 Q2	353.46 Million KRW	-98.84%
2020 FY	15.77 Billion KRW	-45.48%
2020 Q4	15.96 Billion KRW	4974.03%
2020 Q3	314.62 Million KRW	-10.99%
2020 Q1	30.41 Billion KRW	4.1%
2019 Q4	29.21 Billion KRW	0.0%
2019 FY	28.93 Billion KRW	-16.4%
2018 FY	34.61 Billion KRW	202.05%
2017 FY	11.45 Billion KRW	0.0%
2016 FY	- KRW	0.0%
2015 FY	- KRW	0.0%
2013 Q3	10.07 Billion KRW	0.0%
2012 FY	9.31 Billion KRW	0.0%

Peer Long Term Debt Comparison of Genexine, Inc.

Name	Long Term Debt	Long Term Debt Difference
HLB Co., Ltd.	17.93 Billion KRW	-26.477%
iNtRON Biotechnology, Inc.	258.29 Million KRW	-8681.218%
BINEX Co., Ltd.	5.57 Billion KRW	-306.597%
Bioneer Corporation	12.5 Billion KRW	-81.451%
Anterogen.Co.,Ltd.	- KRW	-Infinity%
MEDIPOST Co., Ltd.	6.99 Billion KRW	-224.256%
CrystalGenomics, Inc.	29.88 Billion USD	24.115%
Helixmith Co., Ltd	151.68 Million KRW	-14853.478%
Chabiotech Co.,Ltd.	95.06 Billion KRW	76.142%
Medy-Tox Inc.	1.22 Billion KRW	-1750.274%
Peptron, Inc.	4.5 Billion KRW	-404.032%
Amicogen, Inc.	70.65 Billion KRW	67.898%
HLB Therapeutics Co.,Ltd.	1.84 Billion KRW	-1132.559%
LegoChem Biosciences, Inc.	528.37 Million KRW	-4192.696%
ALTEOGEN Inc.	1.24 Billion KRW	-1715.594%
PharmaResearch Co., Ltd.	970.71 Million KRW	-2236.565%
SillaJen, Inc.	8.13 Billion KRW	-178.784%
JETEMA, Co., Ltd.	60 Billion KRW	62.198%
OliX Pharmaceuticals,Inc	35.36 Billion KRW	35.859%
Genomictree Inc.	97.51 Million KRW	-23159.275%
MedPacto, Inc.	1.68 Billion KRW	-1244.526%
D&D Pharmatech	5.12 Billion KRW	-342.943%
EASY BIO,Inc.	30 Billion KRW	24.395%
GI Innovation, Inc.	2.9 Billion KRW	-681.039%